Navigation Links
Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Date:7/19/2012

f the results in humans are similar to the preclinical data, many more patients will benefit from islet cell transplantation," said Steven J. Mento, President and Chief Executive Officer of Conatus Pharmaceuticals.

The trial will be conducted in two sequential pilot study groups of six patients each with two different dosages of emricasan for 14 days.  Once optimal dosing has been determined from these pilot studies, the next proposed study would be a randomized, placebo-controlled study to explore the safety and efficacy of emricasan combined with other islet transplant treatment medications.

Emricasan is a novel small molecule inhibitor of activated caspases. Caspases are enzymes responsible for executing apoptotic pathways, or programmed cell death and are also involved in processing cytokines involved in inflammation. Conatus is planning Phase 3 clinical trials early next year to test emricasan as a treatment in patients for acute liver failure with underlying cirrhosis, and in patients with liver fibrosis. Emricasan has shown specificity in assays measuring caspase inhibition, and reduced apoptosis in a variety of cellular assays. It also demonstrated efficacy in a number of preclinical models of liver disease and islet transplantation as well as in models of damage to other organ systems. Positive Phase 2 data in a 12-week study in patients with chronic Hepatitis C virus (HCV) infection have indicated that the oral formulation of emricasan was well tolerated, and significantly improved key markers of liver damage as early as 7 days after initiation of therapy.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics in the areas of fibrotic disease and oncology. Conatus' lead drug candidate, emricasan (IDN-6556) is in development primarily as a potential therapy for a variety of fibrotic diseases. Fibrotic diseases affect millions of people worldwide and can
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
2. Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
3. Global Angiogenesis Inhibitors and Stimulators Industry
4. Global Markets for Enzyme Inhibitors
5. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
6. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
9. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
10. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
11. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... HILL, N.C. , July 11, 2014 /PRNewswire/ ... analysis approaches are evolving across industry sectors to ... now examining better ways to engage with and ... consumers inform themselves and make critical purchasing decisions. ... benchmarking firm, Best Practices, LLC, one area where ...
(Date:7/11/2014)... Research and Markets  has announced the ... report to their offering. ... a hollow needle commonly used with a syringe to ... fluids from it. A hypodermic needle is used for ... cannot be ingested. Hypodermic needles are broadly classified into ...
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
(Date:7/14/2014)... 13, 2014 (HealthDay News) -- Eye tests could be ... Alzheimer,s disease, two new studies suggest. In one ... certain eye test found a significant association between levels ... and levels of the plaques in the brain. Beta-amyloid ... This type of eye test could be used ...
(Date:7/14/2014)... MONDAY, July 14, 2014 (HealthDay News) -- Being physically ... risk for Alzheimer,s disease and other types of dementia, ... our studies, we found that physical exercise at various ... Dr. Yonas Geda from the Mayo Clinic, said in ... results, but they are not yet conclusive. More research ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 ... multiple health issues, but dementia isn,t one of them, according ... even delay dementia, the researchers found. "For those who ... with a later age of developing full-blown dementia compared to ... Woodruff, an assistant professor of neurology at the ...
(Date:7/14/2014)... 14, 2014 Follow ... liquid chromatography or UPLC is a new ... chromatography that involves the use of extremely ... separate chromatographic compounds. This highly sensitive qualitative ... and analysis of chromatography samples. UPLC functions ...
(Date:7/14/2014)... Clara, California (PRWEB) July 14, 2014 ... America for the 6th Annual 5K run and one-mile ... America, winds through the park attractions, and finishes inside ... event has raised over $150,000 for the Mission City ... throughout Santa Clara County. , Seasoned athletes, part-time ...
Breaking Medicine News(10 mins):Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Staying Active May Help Prevent Dementia 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2
... on its services for individuals living with autism, and sharing the results ... the services and supports that families living with autism desperately need. ... ... shining the spotlight on its services for individuals living with autism, and ...
... the Family" with Allen Cardoza , Los Angeles, ... ANGELES, April 2 Our special guest this week ... successful private practice. Shelly has been a coach and ... corporate organizations as a Doctor of Psychology and a ...
... how a small hospital improved charge capture performance, ... using Craneware,s Bill AnalyzerATLANTA, April 2 Craneware, ... of financial performance solutions, announced today it will ... at the annual conference of the Healthcare Information ...
... The following is a statement from Jeff Levi, PhD, ... to the release of the new report Beyond Health ... Wood Johnson Foundation Commission to Build a Healthier America:"Every American ... or she can be. And every community should be ...
... Take Place on May 2; ... on May 9 LOS ANGELES, April 2 Revlon (NYSE: REV ... Jennifer Connelly and Jessica Alba along with NBC late night host ... in New York taking place on Saturday, May 2, 2009 , while ...
... with the glitazone class of diabetes drugs leads to ... edema (DME)a common complication that can lead to vision ... the American Journal of Ophthalmology ( http://www.elsevier.com/locate/ajo ... about 170,000 patients with diabetes, Drs. Donald S. Fong ...
Cached Medicine News:Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 2Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 3Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 4Health News:Easter Seals Celebrates World Autism Awareness Day, Hosting Series of Community Forums to Identify Needed Services and Supports for Families 5Health News:Craneware and St. Joseph to Present Revenue Enhancement Success Story at HIMSS 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 2Health News:Trust for America's Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America 3Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 2Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 3Health News:Jessica Alba, Christina Applegate, Jennifer Connelly, Miley Cyrus & Jimmy Fallon on Board to Host Entertainment Industry Foundation's 2009 Revlon Run/Walk 4Health News:Diabetes drug class linked to vision-threatening complication 2
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: